2026-01-10 - Analysis Report
Okay, let's break down the provided information on TG Therapeutics (TGTX).

**0. Overview:**

*   **Company Overview:** TG Therapeutics Inc is a biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

**1. Return Rate Comparison with S&P 500 (VOO):**

*   **TGTX Cumulative Return:** 76.11%
*   **VOO Cumulative Return:** 92.74%
*   **Divergence:** -21.9
*   **Relative Divergence:** 15.5

**Analysis:** TGTX has underperformed the S&P 500 (VOO) based on the cumulative return. The divergence of -21.9 indicates that TGTX's return is 21.9 percentage points lower than the S&P 500's return over the given period.  The relative divergence of 15.5 suggests that this underperformance is currently towards the lower end of its historical range relative to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha  | Beta | Cap(B) |
|------------|---------|-------|--------|------|--------|
| 2016-2018  | -53.0%  | 71.9% | -56.0% | 1.8  | 0.6    |
| 2017-2019  | 71.0%   | 71.9% | 54.0%  | 1.8  | 1.6    |
| 2018-2020  | 332.0%  | 71.9% | 311.0% | 1.6  | 7.7    |
| 2019-2021  | 130.0%  | 66.3% | 86.0%  | 1.6  | 2.8    |
| 2020-2022  | -86.0%  | 90.0% | -84.0% | 1.9  | 1.8    |
| 2021-2023  | -315.0% | 89.7% | -316.0%| 2.4  | 2.5    |
| 2022-2024  | 57.0%   | 76.8% | 38.0%  | 2.3  | 4.5    |
| 2023-2025  | 67.0%   | 76.8% | 4.0%   | 1.1  | 4.4    |

**Analysis:**

*   **CAGR:**  Shows significant volatility in annual growth, ranging from massive gains (332% in 2018-2020) to substantial losses (-315% in 2021-2023).
*   **MDD:** High Maximum Drawdown (MDD) across all periods indicates significant risk and volatility.
*   **Alpha:** Alpha measures the excess return compared to the market.  The Alpha values reflect the wide swings in performance, significantly outperforming the market in some periods and severely underperforming in others.
*   **Beta:**  Beta is consistently above 1, suggesting that TGTX is more volatile than the market. The Beta values have varied over time, indicating changes in the stock's sensitivity to market movements. In recent periods, Beta is higher.
*   **Cap(B):** Shows Market capitalization in Billions.

**2. Recent Stock Price Fluctuations:**

*   **Close:** 30.5
*   **Last-market:** Price: 28.47, Previous Close: 30.5, Change: -6.66
*   **5-day SMA:** 29.89
*   **20-day SMA:** 30.57
*   **60-day SMA:** 31.96

**Analysis:** The stock price has recently declined, closing at 28.47, a 6.66% decrease from the previous close.  The 5-day SMA is below the 20-day SMA, which is below the 60-day SMA, suggesting a short-term downtrend. The larger decrease in the last market indicates an acceleration of the downward trend.

**3. Technical Indicators and Expected Return:**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 45.64 (Neutral)
*   **PPO:** 0.08 (Neutral)
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (26 shares - Caution - MRI:0.70)
*   **Recent (20 days) relative divergence change:** -1.9 (Short-term decrease)
*   **Expected Return (%):** -76.1%

**Analysis:**

*   **MRI:** The MRI of 0.7 suggests a medium level of investment risk.
*   **RSI:**  The RSI is around 45, indicating neither overbought nor oversold conditions.
*   **PPO:** The PPO at 0.08 suggests that the short-term moving average is slightly above the long-term moving average, which is a neutral signal.
*   **Hybrid Signal:** Recommends buying, but with caution due to the MRI. It suggests that the system recommends that you use 80% of your cash to buy 26 shares. The cash ratio will be 0% on 2026-01-08.
*   **Recent Divergence Change:** The negative change in relative divergence indicates a short-term decline relative to the comparison stock.
*   **Expected Return:** The very negative expected return (-76.1%) suggests that the model projects poor returns for TGTX over the long term and would underperform the S&P 500 if invested long-term.

**4. Recent News & Significant Events (Yahoo Finance):**

*   **[2026-01-09] TGTX stock drops 7% as JPMorgan healthcare conference nears:**  Indicates recent negative price action, potentially tied to investor expectations around the conference.
*   **[2025-12-30] TG Therapeutics: What Wall Street Isn't Telling You:** Suggests potential disconnects between analyst sentiment and market realities.
*   **[2025-10-31] TGTX Stock Has Shown Weakness Lately But Financials Look Strong:** Highlights a possible divergence between stock performance and underlying fundamentals.
*   **[2025-11-03] The Earnings Caveat That Sent This Hot Biotech Diving:**  Points to a specific earnings-related issue that negatively impacted the stock.
*   **[2026-01-09] Can TGTX stock rebound after recent weakness:** Indicates general weakness of the company.
*   **[2025-12-19] Is the Options Market Predicting a Spike in TGTX Stock?:**  Suggests potential for a short-term price increase based on options market activity.

**Analysis:** The news headlines paint a mixed picture, with recent negative price action dominating.  Concerns about earnings and analyst perspectives exist alongside potential for a rebound.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy
*   **Mean Rating:** 1.67 (Buy)
*   **Opinions:** 7
*   **Target Price (avg/high/low):** 44.57 / 60.00 / 15.00
*   **Recent Rating Changes:** No rating changes indicated.

**Analysis:**  Despite the recent negative price action and poor expected return, analysts generally have a "Buy" rating on the stock with significant price upside potential (average target of $44.57). However, there is a wide range in target prices, which suggests a lack of conviction.

**5. Recent Earnings Analysis:**

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-11-05 | 2.69 | 0.16 B$   |
| 2025-08-08 | 0.19 | 0.14 B$   |
| 2025-05-09 | 0.03 | 0.12 B$   |
| 2024-11-07 | 0.03 | 0.08 B$   |
| 2025-11-05 | 0.03 | 0.08 B$   |

**Analysis:** The earnings data shows increasing revenue over the past few quarters. The EPS fluctuated heavily.

**6. Financial Information**

Revenue and Profitability:

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $0.16B    | 82.63%        |
| 2025-06-30   | $0.14B    | 86.58%        |
| 2025-03-31   | $0.12B    | 87.14%        |
| 2024-12-31   | $0.11B    | 85.77%        |
| 2024-09-30   | $0.08B    | 88.86%        |

Capital and Profitability:

| Quarter      | Equity    | ROE   |
|--------------|-----------|-------|
| 2025-09-30   | $0.61B    | 64.37%|
| 2025-06-30   | $0.28B    | 10.20%|
| 2025-03-31   | $0.24B    | 2.13% |
| 2024-12-31   | $0.22B    | 10.49%|
| 2024-09-30   | $0.19B    | 2.02% |

**Analysis:** Revenue has been steadily increasing over the past year, which is a positive sign. Profit margins are consistently high. Equity is also increasing, and ROE has seen a significant increase in the most recent quarter, suggesting improved profitability relative to equity.

**7. Comprehensive Analysis:**

TGTX presents a high-risk, high-reward situation. The company has demonstrated strong revenue growth and high profit margins. However, the stock has underperformed the broader market, exhibiting significant volatility and recent downward price action. While analysts maintain a "Buy" rating, the poor expected return and recent negative news headlines warrant caution.

**Key Considerations:**

*   **Volatility:**  TGTX is significantly more volatile than the market.
*   **Recent Downtrend:** The stock is currently in a short-term downtrend.
*   **Analyst Optimism vs. Model Pessimism:**  Analysts have a generally positive outlook, while the model projects poor long-term returns.
*   **Earnings Impact:** Watch for potential earnings-related catalysts.

**In Conclusion:**

TGTX is a speculative investment.  Investors should carefully consider their risk tolerance and conduct further due diligence before investing. The high Beta, recent negative price action, and poor expected return should be weighed against the positive analyst ratings and growing revenue.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.